(BKD) Brookdale Senior Living - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 3.195m USD | Total Return: 104.6% in 12m
Avg Turnover: 42.2M
Qual. Beats: 1
Rev. Trend: 97.7%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
High Debt/EBITDA (16.6) with thin interest coverage (0.2)
Interest Coverage Ratio 0.2 is critical
Altman Z'' -2.65 < 1.0 - financial distress zone
Tailwinds
Idiosyncratic Leader
Brookdale Senior Living Inc. (BKD) is a Brentwood, Tennessee-based provider of senior housing, operating across three primary segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The company’s portfolio includes owned, leased, and managed properties designed to provide tiered care levels ranging from basic residential services to specialized 24-hour assistance for residents with Alzheimer’s or dementia.
The senior living sector operates on a private-pay model for most independent and assisted living services, differentiating it from skilled nursing facilities that rely heavily on government reimbursement. As an operator of CCRCs, Brookdale utilizes a continuum-of-care strategy intended to retain residents within their ecosystem as their medical and physical needs increase over time.
Investors can further evaluate these operational segments and financial metrics by visiting ValueRay.
- Occupancy rate recovery across independent and assisted living segments drives revenue growth
- Labor cost inflation and nursing staff shortages pressure operational margins
- Favorable demographic shifts in the aging U.S. population increase long-term demand
- High debt leverage and interest rate sensitivity impact net income and liquidity
- Strategic portfolio optimization through asset sales and lease restructuring improves cash flow
| Net Income: -204.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 0.29 > 1.0 |
| NWC/Revenue: 12.60% < 20% (prev -3.37%; Δ 15.98% < -1%) |
| CFO/TA 0.04 > 3% & CFO 215.5m > Net Income -204.6m |
| Net Debt (6.45b) to EBITDA (389.1m): 16.58 < 3 |
| Current Ratio: 3.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (238.1m) vs 12m ago 3.22% < -2% |
| Gross Margin: 14.32% > 18% (prev 0.27%; Δ 1.40k% > 0.5%) |
| Asset Turnover: 51.39% > 50% (prev 48.60%; Δ 2.79% > 0%) |
| Interest Coverage Ratio: 0.19 > 6 (EBITDA TTM 389.1m / Interest Expense TTM 253.7m) |
| A: 0.07 (Total Current Assets 552.5m - Total Current Liabilities 160.6m) / Total Assets 5.90b |
| B: -0.73 (Retained Earnings -4.31b / Total Assets 5.90b) |
| C: 0.01 (EBIT TTM 47.3m / Avg Total Assets 6.05b) |
| D: -0.72 (Book Value of Equity -4.31b / Total Liabilities 5.95b) |
| Altman-Z'' = -2.65 = D |
| DSRI: 1.08 (Receivables 64.4m/57.9m, Revenue 3.11b/3.02b) |
| GMI: 1.91 (GM 14.32% / 27.40%) |
| AQI: 1.10 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 1.03 (Revenue 3.11b / 3.02b) |
| TATA: -0.07 (NI -204.6m - CFO 215.5m) / TA 5.90b) |
| Beneish M = -2.13 (Cap -4..+1) = BB |
As of May 27, 2026, the stock is trading at USD 13.48 with a total of 2,012,461 shares traded.
Over the past week, the price has changed by +1.51%,
over one month by -3.37%,
over three months by -11.14% and
over the past year by +104.55%.
Brookdale Senior Living has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold BKD.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 19.1 | 41.7% |
P/E Forward = 47.619
P/S = 1.0647
P/B = 18.976
P/EG = 0.2804
Revenue TTM = 3.11b USD
EBIT TTM = 47.3m USD
EBITDA TTM = 389.1m USD
Long Term Debt = 4.22b USD (from longTermDebt, last quarter)
Short Term Debt = 160.6m USD (from shortTermDebt, last quarter)
Debt = 6.72b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.21b
Net Debt = 6.45b USD (calculated: Debt 6.72b - CCE 270.1m)
Enterprise Value = 9.65b USD (3.20b + Debt 6.72b - CCE 270.1m)
Interest Coverage Ratio = 0.19 (Ebit TTM 47.3m / Interest Expense TTM 253.7m)
EV/FCF = 1000.0x (Enterprise Value 9.65b / FCF TTM 9.32m)
FCF Yield = 0.10% (FCF TTM 9.32m / Enterprise Value 9.65b)
FCF Margin = 0.30% (FCF TTM 9.32m / Revenue TTM 3.11b)
Net Margin = -6.58% (Net Income TTM -204.6m / Revenue TTM 3.11b)
Gross Margin = 14.32% ((Revenue TTM 3.11b - Cost of Revenue TTM 2.66b) / Revenue TTM)
Gross Margin QoQ = 3.33% (prev -1.18%)
Tobins Q-Ratio = 1.64 (Enterprise Value 9.65b / Total Assets 5.90b)
Interest Expense / Debt = 3.77% (Interest Expense 253.7m / Debt 6.72b)
Taxrate = 21.0% (US default 21%)
NOPAT = 37.4m (EBIT 47.3m * (1 - 21.00%))
Current Ratio = 3.44 (Total Current Assets 552.5m / Total Current Liabilities 160.6m)
Debt / Equity = -120.2 (out of range, set to none) (Debt 6.72b / totalStockholderEquity, last quarter -55.9m)
Debt / EBITDA = 16.58 (Net Debt 6.45b / EBITDA 389.1m)
Debt / FCF = 692.2 (Net Debt 6.45b / FCF TTM 9.32m)
Total Stockholder Equity = -510k (last 4 quarters mean from totalStockholderEquity)
RoA = -3.38% (Net Income -204.6m / Total Assets 5.90b)
RoE = -4.75% (Net Income TTM -204.6m / Total Stockholder Equity 4.31b)
RoCE = 0.55% (EBIT 47.3m / Capital Employed (Equity 4.31b + L.T.Debt 4.22b))
RoIC = 0.63% (NOPAT 37.4m / Invested Capital 5.90b)
WACC = 4.21% (E(3.20b)/V(9.92b) * Re(6.79%) + D(6.72b)/V(9.92b) * Rd(3.77%) * (1-Tc(0.21)))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 2.46%
[DCF] Terminal Value 75.44% ; FCFF base≈9.32m ; Y1≈9.36m ; Y5≈9.92m
[DCF] Fair Price = N/A (negative equity: EV 154.2m - Net Debt 6.45b = -6.30b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.00 | # QB: 1
Revenue Correlation: 97.71 | Revenue CAGR: 3.83% | SUE: -0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.09 | Chg30d=-13.33% | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.06 | Chg30d=+20.00% | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.14 | Chg30d=+49.09% | Revisions=+20% | GrowthEPS=+81.1% | GrowthRev=-6.1%
EPS next Year (2027-12-31): EPS=0.04 | Chg30d=N/A | Revisions=+20% | GrowthEPS=+125.0% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: -20%